---
title: "Helus Ekes up on Hookup with TARA Mind"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/284405613.md"
description: "Helus Pharma™ (NASDAQ: HELP) announced a collaboration with TARA Mind to support clinical trial recruitment for its PARADIGM HLP003 Phase 3 program targeting Major Depressive Disorder, particularly within the veteran community. This partnership aligns with President Trump's Executive Order aimed at enhancing clinical research participation for veterans facing mental health challenges. Helus Pharma's shares rose by 2.5 cents to $5.42 as they emphasize the importance of expanding access to innovative treatments for serious mental illness."
datetime: "2026-04-28T14:17:20.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/284405613.md)
  - [en](https://longbridge.com/en/news/284405613.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/284405613.md)
---

# Helus Ekes up on Hookup with TARA Mind

Helus Pharma™ (NASDAQ: HELP) shares forged ahead Tuesday. The New York-based company, a clinical stage pharmaceutical concern committed to helping minds heal by developing novel serotonergic agonists announced a collaboration with TARA Mind, which works with Veterans Exploring Treatment Solutions to support clinical trial recruitment for its PARADIGM HLP003 Phase 3 program for Major Depressive Disorder, while expanding mental health awareness and access within the veteran community.

This partnership directly aligns with President Trump’s April 18, Executive Order, “Accelerating Medical Treatments for Serious Mental Illness,” which emphasizes expanding clinical research participation and advancing innovative treatment approaches for populations, including veterans, who face disproportionately high rates of depression, PTSD, and suicide.

“Veterans face significant mental health challenges, and expanding awareness and access to clinical research opportunities is an important step toward improving outcomes,” said Eric So, Interim Chief Executive Officer of Helus Pharma.

“TARA Mind and VETS bring deep experience working with veteran communities. These collaborations will support recruitment efforts for our FDA Breakthrough Therapy-designated HLP003 program while aligning with the broader priorities highlighted in the recent Executive Order to expand research participation and advance innovative treatments for serious mental illness.”

HELP shares edged ahead 2.5 cents to $5.42.

### Related Stocks

- [HELP.US](https://longbridge.com/en/quote/HELP.US.md)
- [CYBN.US](https://longbridge.com/en/quote/CYBN.US.md)

## Related News & Research

- [Helus Pharma Backs U.S. Executive Order Accelerating Psychedelic Treatment Pathways](https://longbridge.com/en/news/283408643.md)
- [Helus Pharma CEO to Spotlight Mental Health Innovation at 29th Milken Global Conference](https://longbridge.com/en/news/284829118.md)
- [Twin Capital Management Inc. Grows Stock Position in UnitedHealth Group Incorporated $UNH](https://longbridge.com/en/news/287213128.md)
- [How Investors May Respond To American Healthcare REIT (AHR) Cutting 2026 Profit Outlook After Q1 Results](https://longbridge.com/en/news/286866277.md)
- [Pepaxti study supports use in wider myeloma population](https://longbridge.com/en/news/287058986.md)